Wedbush Has Negative Forecast for NBIX Q1 Earnings

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Analysts at Wedbush decreased their Q1 2026 EPS estimates for shares of Neurocrine Biosciences in a report issued on Tuesday, May 6th. Wedbush analyst L. Chico now anticipates that the company will post earnings of $1.10 per share for the quarter, down from their previous forecast of $1.31. Wedbush currently has a "Outperform" rating on the stock. The consensus estimate for Neurocrine Biosciences' current full-year earnings is $4.28 per share. Wedbush also issued estimates for Neurocrine Biosciences' Q2 2026 earnings at $1.41 EPS, Q3 2026 earnings at $1.58 EPS and Q4 2026 earnings at $1.68 EPS.

NBIX has been the subject of several other research reports. BMO Capital Markets boosted their price target on shares of Neurocrine Biosciences from $96.00 to $115.00 and gave the stock a "market perform" rating in a report on Tuesday. Evercore ISI cut their target price on shares of Neurocrine Biosciences from $190.00 to $185.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. William Blair reaffirmed an "outperform" rating on shares of Neurocrine Biosciences in a research note on Friday, February 7th. JPMorgan Chase & Co. boosted their price objective on Neurocrine Biosciences from $183.00 to $184.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 26th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on Neurocrine Biosciences in a research report on Tuesday, February 11th. They issued a "hold" rating and a $138.00 target price on the stock. Three research analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company. According to MarketBeat, Neurocrine Biosciences has an average rating of "Moderate Buy" and a consensus price target of $162.00.

Neurocrine Biosciences Price Performance

Neurocrine Biosciences stock opened at $121.54 on Thursday. The stock has a market capitalization of $12.02 billion, a PE ratio of 36.94, a price-to-earnings-growth ratio of 0.77 and a beta of 0.26. The business has a 50 day simple moving average of $106.12 and a 200-day simple moving average of $121.80. Neurocrine Biosciences has a 12 month low of $84.23 and a 12 month high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $0.08 EPS for the quarter, missing analysts' consensus estimates of $0.70 by ($0.62). The business had revenue of $572.60 million for the quarter, compared to analyst estimates of $587.06 million. Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. Neurocrine Biosciences's revenue was up 11.1% on a year-over-year basis. During the same quarter last year, the business earned $1.20 earnings per share.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. OneDigital Investment Advisors LLC increased its holdings in Neurocrine Biosciences by 2.1% in the fourth quarter. OneDigital Investment Advisors LLC now owns 4,215 shares of the company's stock valued at $575,000 after buying an additional 87 shares in the last quarter. HighPoint Advisor Group LLC boosted its position in Neurocrine Biosciences by 4.1% during the fourth quarter. HighPoint Advisor Group LLC now owns 2,446 shares of the company's stock worth $334,000 after purchasing an additional 96 shares in the last quarter. Huntington National Bank grew its holdings in Neurocrine Biosciences by 73.5% in the fourth quarter. Huntington National Bank now owns 229 shares of the company's stock valued at $31,000 after purchasing an additional 97 shares during the last quarter. Louisiana State Employees Retirement System increased its position in shares of Neurocrine Biosciences by 0.4% in the fourth quarter. Louisiana State Employees Retirement System now owns 28,100 shares of the company's stock valued at $3,836,000 after buying an additional 100 shares in the last quarter. Finally, Utah Retirement Systems raised its stake in shares of Neurocrine Biosciences by 0.6% during the 4th quarter. Utah Retirement Systems now owns 16,583 shares of the company's stock worth $2,264,000 after buying an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 92.59% of the company's stock.

Insider Buying and Selling

In other news, insider Julie Cooke sold 700 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $118.28, for a total value of $82,796.00. Following the sale, the insider now directly owns 18,831 shares in the company, valued at approximately $2,227,330.68. This trade represents a 3.58 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kyle Gano sold 980 shares of the business's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $118.39, for a total value of $116,022.20. Following the transaction, the chief executive officer now directly owns 137,658 shares of the company's stock, valued at $16,297,330.62. The trade was a 0.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 43,907 shares of company stock valued at $4,935,982 in the last ninety days. Company insiders own 4.30% of the company's stock.

Neurocrine Biosciences declared that its Board of Directors has initiated a share repurchase program on Friday, February 21st that allows the company to buyback $500.00 million in shares. This buyback authorization allows the company to buy up to 4.2% of its stock through open market purchases. Stock buyback programs are usually an indication that the company's management believes its stock is undervalued.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.